Search Results - "Kiguchi, Toru"

Maintenance therapy for acute myeloid leukemia (including in patients who have undergone transplantation) including off-label use drugs in Japan by Kiguchi, Toru

“…Recurrence in acute myeloid leukemia (AML) is a major barrier in patients who achieve complete remission after induction of remission and consolidation therapy…”
Get more information

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan by Ikezoe, Takayuki, Ando, Kiyoshi, Onozawa, Masahiro, Yamane, Takahisa, Hosono, Naoko, Morita, Yasuyoshi, Kiguchi, Toru, Iwasaki, Hiromi, Miyamoto, Toshihiro, Matsubara, Keisuke, Sugimoto, Saori, Miyazaki, Yasushi, Kizaki, Masahiro, Akashi, Koichi

“…Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment‐refractory (R/R)…”
Get full text

State-of-the-art treatment of acute promyelocytic leukemia by Kiguchi, Toru

“…Acute promyelocytic leukemia (APL) with PML-RARA is an acute myeloid leukemia (AML) with a predominance of abnormal promyelocytes. Both hypergranular (typical)…”
Get more information

Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial by Kiguchi, Toru, Yamaguchi, Masaki, Takezako, Naoki, Miyawaki, Shuichi, Masui, Koichi, Ihara, Yuichiro, Hirota, Masao, Shimofurutani, Naoko, Naoe, Tomoki

“…Purpose Complete remission (CR) of acute myeloid leukemia (AML) in elderly patients has a short duration, and there is no suitable post-remission therapy. We…”
Get full text

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study by Sunami, Kazutaka, Suzuki, Kenshi, Ri, Masaki, Matsumoto, Morio, Shimazaki, Chihiro, Asaoku, Hideki, Shibayama, Hirohiko, Ishizawa, Kenichi, Takamatsu, Hiroyuki, Ikeda, Takashi, Maruyama, Dai, Kaneko, Hitomi, Uchiyama, Michihiro, Kiguchi, Toru, Iyama, Satoshi, Murakami, Hirokazu, Takahashi, Keishiro, Tada, Keisuke, Macé, Sandrine, Guillemin‐Paveau, Hélène, Iida, Shinsuke

“…Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm,…”
Get full text

Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan by Kiguchi, Toru, Hiramatsu, Yasushi, Ota, Shuichi, Uchiyama, Michihiro, Matsuo, Moe, Okamura, Miyu, Morimoto, Shimpei, Tanizawa, Yoshinori, Tajimi, Masaomi, Payakachat, Nalin

“…The increasing number of treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)…”
Get full text

Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey by Miyamoto, Toshihiro, Iino, Masaki, Komorizono, Yasuji, Kiguchi, Toru, Furukawa, Nobufusa, Otsuka, Maki, Sawada, Shohei, Okamoto, Yutaka, Yamauchi, Kenji, Muto, Toshitaka, Fujisaki, Tomoaki, Tsurumi, Hisashi, Nakamura, Kimitoshi

“…Objective For patients with Gaucher disease (GD), a rare, inherited lysosomal storage disease, obtaining a definitive diagnosis is currently time-consuming and…”
Get full text

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia by Sekiguchi, Naohiro, Kasahara, Senji, Miyamoto, Toshihiro, Kiguchi, Toru, Ohno, Hitoshi, Takagi, Taiga, Tachibana, Masaya, Sumi, Hiroyuki, Kakurai, Yasuyuki, Yamashita, Tomonari, Usuki, Kensuke

“…Long-term survival in patients with acute myeloid leukemia (AML) remains low, and current treatment modalities are inadequate. Milademetan (DS-3032, RAIN-32),…”
Get full text

A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients by Chen, Shurui, Kiguchi, Toru, Nagata, Yasuyuki, Tamai, Yotaro, Ikeda, Takeshi, Kajiya, Ryoko, Ono, Takaaki, Sugiyama, Daisuke, Nishikawa, Hiroyoshi, Akatsuka, Yoshiki

“…Negative immunofixation electrophoresis (IFE) of serum and/or urine is a diagnostic marker for determining a complete response (CR) after immunotherapy for…”
Get full text

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma by Murayama, Kayoko, Kiguchi, Toru, Izutsu, Koji, Kameoka, Yoshihiro, Hidaka, Michihiro, Kato, Harumi, Rai, Shinya, Kuroda, Junya, Ishizawa, Kenichi, Ichikawa, Satoshi, Ando, Kiyoshi, Ogura, Michinori, Fukushima, Koji, Terui, Yasuhito

“…This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory…”
Get full text

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 by Ishikawa, Yuichi, Kawashima, Naomi, Atsuta, Yoshiko, Sugiura, Isamu, Sawa, Masashi, Dobashi, Nobuaki, Yokoyama, Hisayuki, Doki, Noriko, Tomita, Akihiro, Kiguchi, Toru, Koh, Shiro, Kanamori, Heiwa, Iriyama, Noriyoshi, Kohno, Akio, Moriuchi, Yukiyoshi, Asada, Noboru, Hirano, Daiki, Togitani, Kazuto, Sakura, Toru, Hagihara, Maki, Tomikawa, Tatsuki, Yokoyama, Yasuhisa, Asou, Norio, Ohtake, Shigeki, Matsumura, Itaru, Miyazaki, Yasushi, Naoe, Tomoki, Kiyoi, Hitoshi

“…The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo…”
Get full text

Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study by Maruyama, Dai, Tobinai, Kensei, Ogura, Michinori, Uchida, Toshiki, Hatake, Kiyohiko, Taniwaki, Masafumi, Ando, Kiyoshi, Tsukasaki, Kunihiro, Ishida, Takashi, Kobayashi, Naoki, Ishizawa, Kenichi, Tatsumi, Yoichi, Kato, Koji, Kiguchi, Toru, Ikezoe, Takayuki, Laille, Eric, Ro, Tokihiro, Tamakoshi, Hiromi, Sakurai, Sanae, Ohtsu, Tomoko

“…This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous…”
Get full text

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma by Izutsu, Koji, Minami, Yosuke, Fukuhara, Noriko, Terui, Yasuhito, Jo, Tatsuro, Yamamoto, Go, Ishikawa, Takayuki, Kobayashi, Tsutomu, Kiguchi, Toru, Nagai, Hirokazu, Ohtsu, Tomoko, Kalambakas, Stacey, Fustier, Pierre, Midorikawa, Shuichi, Tobinai, Kensei

“…Patients with indolent non-Hodgkin lymphoma (iNHL) typically respond to first-line immunochemotherapy, but relapse is common. Treatment options for relapsed…”
Get full text

Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study) by Murakami, Hirokazu, Kasamatsu, Tetsuhiro, Murakami, Jun, Kiguchi, Toru, Kanematsu, Takeshi, Ogawa, Daisuke, Takamatsu, Hiroyuki, Handa, Hiroshi, Ozaki, Shuji, Miki, Hirokazu, Takahashi, Takeshi, Takeo, Takaaki, Yamauchi, Tatsuya, Morishita, Takanobu, Kosugi, Hiroshi, Shimizu, Kazuyuki

“…A prospective, multicenter, phase II study was performed to assess the efficacy and safety of thalidomide maintenance therapy at different doses in Japanese…”
Get full text

Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol by Tamura, Kazuo, Kawai, Yasukazu, Kiguchi, Toru, Okamoto, Masataka, Kaneko, Masahiko, Maemondo, Makoto, Gemba, Kenichi, Fujimaki, Katsumichi, Kirito, Keita, Goto, Tetsuya, Fujisaki, Tomoaki, Takeda, Kenji, Nakajima, Akihiro, Ueda, Takanori

“…Background Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis…”
Get full text

Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial by Miyazaki, Yasushi, Kiguchi, Toru, Sato, Shinya, Usuki, Kensuke, Ishiyama, Ken, Ito, Yoshikazu, Suzuki, Takahiro, Taguchi, Jun, Chiba, Shigeru, Dobashi, Nobuaki, Tomita, Akihiro, Harada, Hironori, Handa, Hiroshi, Horiike, Shigeo, Maeda, Tomoya, Matsuda, Mitsuhiro, Ichikawa, Motoshi, Hata, Tomoko, Honda, Sumihisa, Iyama, Satoshi, Suzushima, Hitoshi, Moriuchi, Yukiyoshi, Kurokawa, Toshiro, Yokota, Kenichi, Ohtake, Shigeki, Yamauchi, Takahiro, Matsumura, Itaru, Kiyoi, Hitoshi, Naoe, Tomoki

“…The hypomethylating agent azacitidine (AZA) significantly extends overall survival (OS) in patients with higher risk myelodysplastic syndromes (MDS), when…”
Get full text

Erratum for Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey by Miyamoto, Toshihiro, Iino, Masaki, Komorizono, Yasuji, Kiguchi, Toru, Furukawa, Nobufusa, Otsuka, Maki, Sawada, Shohei, Okamoto, Yutaka, Yamauchi, Kenji, Muto, Toshitaka, Fujisaki, Tomoaki, Tsurumi, Hisashi, Nakamura, Kimitoshi

Get full text

Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study by Matsue, Kosei, Kumagai, Kyoya, Sugiura, Isamu, Ishikawa, Takayuki, Igarashi, Tadahiko, Sato, Tsutomu, Uchiyama, Michihiro, Miyamoto, Toshihiro, Ono, Takaaki, Ueda, Yasunori, Kiguchi, Toru, Sunaga, Yoshinori, Sasaki, Toru, Suzuki, Kenshi

“…The present study (ClinicalTrials.gov Identifier: NCT02221492) was conducted to assess the efficacy and safety of plerixafor for the mobilization and…”
Get full text

A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia by Iida, Hiroatsu, Imada, Kazunori, Ueda, Yasunori, Kubo, Kohmei, Yokota, Akira, Ito, Yoshikazu, Kiguchi, Toru, Hata, Tomoko, Nawa, Yuichiro, Ikezoe, Takayuki, Uchida, Toshiki, Morita, Yasuyoshi, Kawashima, Ichiro, Chiba, Masahiro, Morimoto, Kensaku, Hirooka, Shihomi, Miyazaki, Yasushi, Ohno, Ryuzo, Naoe, Tomoki

“…A multicenter phase II study was conducted in 44 elderly (≥ 65 years) Japanese patients with newly diagnosed acute myeloid leukemia (AML) to evaluate whether…”
Get full text

A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan by Ogawa, Yoshiaki, Izutsu, Koji, Kiguchi, Toru, Choi, Ilseung, Takatsuka, Yoshifusa, Ando, Kiyoshi, Suzumiya, Junji

“…The present study was intended to examine the efficacy and safety of bendamustine monotherapy in patients with previously untreated chronic lymphocytic…”
Get full text